<DOC>
	<DOCNO>NCT02276248</DOCNO>
	<brief_summary>This study evaluate efficacy safety radiotherapy combine GDP ( gemcitabine , cisplatin , dexamethasone ) chemotherapy stage I/II extranodal natural killer/T-cell lymphoma patient unfavorable prognostic factor .</brief_summary>
	<brief_title>Radiotherapy Combined With GDP Chemotherapy Stage I/II Extranodal Natural Killer/T-cell Lymphoma</brief_title>
	<detailed_description>Radiotherapy recognize definitive treatment choice stage I II extranodal NK/T cell lymphoma . The progression-free survival rate overall survival rate radiotherapy plus anthracycline-containing chemotherapy comparable radiotherapy alone . Our previous study demonstrate high responsiveness safety GDP ( gemcitabine , cisplatin , dexamethasone ) regimen patient extranodal NK/T cell lymphoma . Therefore , design study evaluate safety benefit radiotherapy plus GDP regimen extranodal NK/T cell lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>1. diagnosis ENKTL typical morphology immunophenotype accord 2008 World Health Organization classification lymphoma ; 2. newlydiagnosed patient ; 3. tumor primarily occur upper aerodigestive tract ( nasal cavity , nasopharynx , oral cavity , oropharynx hypopharynx ) ; 4 . Ann Arbor stage I/II ; 5. age ≥ 18 year ; 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ; 7. least one measurable lesion ; 8. adequate hematologic , hepatic , renal function : absolute neutrophil count ≥ 1.5×109/l , platelet count ≥ 100×109/l , total bilirubin ≤ 1.5 × upper limit normal , AST ALT ≤ 2 × upper limit normal , creatinine ≤ 1.5 mg/dl ; 9. least one unfavorable prognostic factor ( age ＞ 60 year ; B symptom ; elevate lactate dehydrogenase ; regional node involvement ; local tumor invasion : bone skin ; histologic elevation high Ki67 staining ) 10. life expectancy 3 month ; 11. informed consent . 1. patient receive prior treatment ; 2. stage I/II patient without unfavorable prognostic factor ; 3. tumor primarily occur extraupper aerodigestive tract ( e.g. , skin , testis , intestine , muscle ) ; 4. pregnant breastfeed woman woman childbearing potential employ adequate contraception ; 5. patient second primary cancer ( except , adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumor curatively treat evidence disease ≥5 year ) 6. patient defect central nervous system ( CNS ) psychiatric disorder CNS metastases 7. serious illness medical condition A. Clinically significant cardiac disease ( uncontrolled congestive heart disease despite treatment [ NYHA class III IV ] , symptomatic coronary artery disease , unstable angina myocardial infarction , conduction abnormality like grade 2 AV block , serious arrhythmia need medication , uncontrolled hypertension ) within 6 month prior study entry B. Liver cirrhosis ( ≥ ChildPugh class B ) C. History significant neurologic psychiatric disorder include dementia seizure D. Active uncontrolled infection E. Other serious underlie medical condition could impair ability patient participate study 8. systemic anticancer therapy within 30 day inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>